Biocon Biologics Limited
Add a review FollowOverview
-
Founded Date January 1, 1978
-
Posted Jobs 3
-
Viewed 26
Company Description
Sharp inequalities in access to advanced therapies have denied the benefits of progress in medical science to almost a third of the world’s population. Hefty price tags on lifesaving drugs have created unbearable financial burden for patients in most of the world. Inadequate research spending has led to a fragile medical innovation ecosystem with serious repercussions on global preparedness for health emergencies.
COVID-19 served as a wake-up call for the global pharmaceutical sector, forcing the community to rapidly innovate and rethink ways of improving access to essential, lifesaving medicines.
Our vision is to be a global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients’ lives.
OUR VALUES
- Value creation through innovation and differentiation
- Quality through compliance and best practices
- Collaboration teamwork and mutual respect
- Integrity and ethical behaviour
- Performance-driven work culture
Poised to Make a Meaningful Difference
Biocon Biologics’ relentless strategic intent to stand out and stand apart has steered us into new growth paths, which include the landmark acquisition of the global biosimilars business of our long-term partner Viatris for over USD 3 billion in cash and stock. It is one of the biggest M&A deals in the Indian pharma space, and a historic inflection point in Biocon Biologics’ value creation journey.
This acquisition is a game changing event that catapults Biocon Biologics into the big league – a unique, fully integrated leading global biosimilars company.
By combining the complementary capabilities and strengths of two long-term partners, we are leveraging THE POWER OF ONE to reduce healthcare inequities and transform healthcare, worldwide.
OUR BUSINESS
Biocon Biologics, headquartered in Bengaluru, India, is a unique, fully integrated leading global biosimilars player with established capabilities in the development, manufacturing and commercialization of high-quality biosimilars.
With a unique portfolio of monoclonal antibodies, insulins and conjugated recombinant proteins for diabetes, cancer, autoimmune diseases, serious eye conditions and bone health, Biocon Biologics is fully committed to the long-term sustainability of global biosimilars access.
BOARD OF DIRECTORS
Biocon Biologics’ Board of Directors provides effective leadership by engaging, enabling and encouraging the management to deliver on the company’s vision and values. The diverse and multidisciplinary group of knowledgeable and experienced professionals serves as a source of advice and counsel. They also act as mentors for the management in value creation, whilst upholding our firm commitment to the highest levels of corporate governance through risk control and regulatory compliance.
